The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria.
 
Sarah S. Lee
No Relationships to Disclose
 
Jingwen Zhang
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Mia Mackall
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Sara L. Bristow
Employment - InVitae; Natera
Stock and Other Ownership Interests - InVitae
 
Meenakshi Malhotra
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Adam ElNaggar
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Vivienne Souter
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Minetta C. Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
Research Funding - Eisai (Inst); Exact Sciences (Inst); Genomic Health (Inst); GRAIL (Inst); Menarini Silicon Biosystems (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; Menarini Silicon Biosystems; Merck; Natera; Pfizer
 
Bhavana Pothuri
Honoraria - Bio Ascend; OncLive; PER; Projects in Knowledge; YALE UNIVERSITY
Consulting or Advisory Role - AstraZeneca; Celsion; Curio Science; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Incyte; Incyte; InxMed; Lilly; Merck; Mersana; Onconova Therapeutics; Peerview; R-Pharm; Regeneron; Seagen; Signatera; Sutro Biopharma; WebMD
Research Funding - Acrivon Therapeutics (Inst); Agenus (Inst); AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); InxMed (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Novocure (Inst); NRG Oncology (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Tesaro (Inst); Toray Industries (Inst); VBL Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - GOG Foundation; Merck; Seagen
Other Relationship - Society of Gynecologic Oncology